Southport Management L.L.C. Invests $678,000 in AstraZeneca plc (AZN)

Southport Management L.L.C. acquired a new position in AstraZeneca plc (NYSE:AZN) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 20,000 shares of the company’s stock, valued at approximately $678,000. AstraZeneca makes up approximately 1.8% of Southport Management L.L.C.’s portfolio, making the stock its 22nd largest position.

Other hedge funds have also bought and sold shares of the company. Fisher Asset Management LLC increased its position in AstraZeneca by 4.7% in the 3rd quarter. Fisher Asset Management LLC now owns 11,601,573 shares of the company’s stock valued at $393,061,000 after buying an additional 519,717 shares in the last quarter. Federated Investors Inc. PA increased its position in AstraZeneca by 3.6% in the 2nd quarter. Federated Investors Inc. PA now owns 4,484,770 shares of the company’s stock valued at $152,885,000 after buying an additional 156,256 shares in the last quarter. Wells Fargo & Company MN increased its position in AstraZeneca by 7.6% in the 3rd quarter. Wells Fargo & Company MN now owns 4,406,824 shares of the company’s stock valued at $149,303,000 after buying an additional 310,389 shares in the last quarter. Ameriprise Financial Inc. increased its position in AstraZeneca by 7.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 3,026,781 shares of the company’s stock valued at $102,643,000 after buying an additional 199,519 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in AstraZeneca by 18.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,558,882 shares of the company’s stock valued at $86,695,000 after buying an additional 395,699 shares in the last quarter. 14.75% of the stock is owned by hedge funds and other institutional investors.

Shares of AstraZeneca plc (NYSE:AZN) opened at $32.09 on Thursday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.72 and a current ratio of 0.94. The company has a market capitalization of $81,527.05, a P/E ratio of 7.68, a price-to-earnings-growth ratio of 3.12 and a beta of 0.72. AstraZeneca plc has a twelve month low of $25.55 and a twelve month high of $35.60.

AstraZeneca (NYSE:AZN) last issued its quarterly earnings data on Thursday, November 9th. The company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.55. The firm had revenue of $6.23 billion during the quarter, compared to analyst estimates of $6 billion. AstraZeneca had a return on equity of 34.02% and a net margin of 15.90%. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.32 EPS. sell-side analysts predict that AstraZeneca plc will post 1.87 earnings per share for the current fiscal year.

A number of brokerages recently commented on AZN. BMO Capital Markets set a $38.00 target price on AstraZeneca and gave the company a “buy” rating in a research report on Wednesday, November 15th. Leerink Swann boosted their target price on AstraZeneca from $31.00 to $34.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. Citigroup raised AstraZeneca to a “buy” rating in a research report on Wednesday, October 18th. Cowen reaffirmed a “hold” rating and issued a $37.00 target price on shares of AstraZeneca in a research report on Tuesday, October 17th. Finally, Credit Suisse Group raised AstraZeneca from a “neutral” rating to an “outperform” rating in a research report on Monday, October 16th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $34.20.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2017/12/07/southport-management-l-l-c-invests-678000-in-astrazeneca-plc-azn.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply